Glucagon-Like Peptides
- Name
- Glucagon-Like Peptides
- Accession Number
- DBCAT001826
- Description
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
- Drugs
Drug Drug Description Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. Teduglutide A glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Taspoglutide Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted... rGLP-1 Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2. BPI-3016 BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects). Beinaglutide Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus). - Drugs & Drug Targets